Human Immunodeficiency Virus – Current Treatment – Detailed, Expanded Analysis (US) Current Treatment: Physician Insights
The human immunodeficiency virus (HIV) therapy market is dynamic and growing. With the launches of many effective antiretroviral therapies (ART), such as Gilead’s Biktarvy and ViiV’s Dovato, Juluca, and Cabenuva (long-acting once-monthly injection), safety and tolerability have become the key differentiating attributes among ART regimens. For the majority of patients, current ARTs such as single-tablet regimens (STRs) have achieved maximal antiretroviral efficacy and tolerability, changing HIV infection from a fatal disease to a tolerable chronic condition. Despite this achievement, adherence to regular oral medicine consumption remains a problem; however, the recent label expansion of Cabenuva, a novel medication delivery strategy, is poised to transform the treatment landscape, reducing the once-daily pill burden to only six intramuscular injections each year. This report focuses on the current treatment and anticipated use of HIV treatment regimens, including recently approved ARTs such as Trogarzo and Rukobia, for heavily treatment-experienced patients with multidrug-resistant HIV-1 infection, by capturing the patient market share data, current prescribing trends, and anticipated changes in prescribing and treatment behavior. The key prescribing drivers and barriers and sales force performance for key brands will be evaluated. This content will quantitatively explore the current treatment of HIV as marketed ARTs and novel agents advance in the pipeline.
Questions answered
- Which comorbidities are the most common among surveyed physicians’ patient populations?
- How do physicians approach the management of newly diagnosed HIV patients and those switching treatment?
- Which patients receive which ART with respect to their CD4-count level?
- Which patients are being prescribed STRs (e.g., Gilead’s Biktarvy, Genvoya, and Odefsey; ViiV’s Juluca, Dovato, and Cabenuva) and in which line(s) of therapy? What factors drive the movement of HIV patients through lines of therapy?
- Which ARTs are the patient-share leaders in HIV? How are key STRs positioned in surveyed physicians’ treatment algorithms?
- What is the sequencing of treatment for HIV?
- What are the most influential drivers of treatment selection in HIV?
- What are the infectious disease physician-reported factors determining current prescribing patterns and recent / anticipated changes?
Content highlights
Markets covered: United States
Key companies: Gilead Sciences, ViiV Healthcare, Janssen, Boehringer Ingelheim, Merck & Co.
Key drugs: Biktarvy, Dovato, Juluca, Cabenuva, Genvoya
Product description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Table of contents
- Human Immunodeficiency Virus - Current Treatment - Detailed, Expanded Analysis (US) Current Treatment: Physician Insights
- Current Treatment: Physician Insights Human Immunodeficiency Virus US May 2022
Sukhvinder Singh, M.Tech., is a senior analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. He has several years of experience providing research and analytics support in the pharmaceutical domain. He has worked in numerous therapy areas, including ophthalmology, dermatology, neurology, and rare diseases. Prior to joining Clarivate, Mr. Singh was an assistant project manager on the forecasting and analytics team at DelveInsight Business Research. He was responsible for preparing epidemiology and market research reports, which included pipeline assessments, sales forecasting, and commercial opportunity assessments. He earned his master’s degree in technology and biotechnology at Amity University in Noida, India.